Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.
Approval Alert | Ensartinib in Metastatic ALK-Positive NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
5
